David Wohl MD

Dr. David Wohl is a Professor of Medicine in the Division of Infectious Diseases at the University of North Carolina (UNC). He is the co-Principal Investigator of the Global UNC Infectious Diseases Clinical Research Unit and Site Leader of its Chapel Hill research site.

Dr. Wohl is a clinical scientist with a focus on emerging infectious diseases. He has spent over 20 years leading research into the prevention and treatment of HIV and served two terms as a member of the US Department of Health and Human Services (DHHS) Antiretroviral Guidelines Panel.

Since 2014, he has been working continuously in Liberia, West Africa, conducting research with Ebola survivors to learn about chronic complications and sexual transmission of this infection and establishing the UNC Project Liberia research platform at two locations in the country. He and his team have extended this work to examine Lassa fever, a viral hemorrhagic fever endemic in West Africa.

In 2020, he contributed to the UNC clinical and research response to COVID-19. He is the medical director of the UNC Chapel Hill drive-through testing site as well as two COVID-19 vaccination clinics and the Chapel Hill COVID-19 monoclonal antibody infusion center. He serves as Vice Chair of ACTIV-2, an international trial of promising SARS-CoV-2 therapeutics. He is the Co-Director of the UNC Regional Emerging Special Pathogens Treatment Center (RESPTC), one of 13 in the US.